Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
04 janv. 2022 08h30 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), today announced it has concluded its End-of-Phase 2 meeting with the U.S. Food and Drug...
Entera Bio Reports Third Quarter 2021 Financial Results
10 nov. 2021 08h30 HE
|
Entera Bio Ltd.
‒ Two Presentations at ASBMR, including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis ‒ ‒ Study Sets Stage for Phase 3 registrational trial in 2022 ‒ BOSTON and...
Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs
28 oct. 2021 08h30 HE
|
Entera Bio Ltd.
‒Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the “Holy Grail” of drug development. ‒Technology is utilized in Entera’s EB613 oral PTH drug for...
Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session
06 oct. 2021 08h30 HE
|
Entera Bio Ltd.
Increases in lumbar spine, femoral neck and total hip BMD demonstrated with EB613 Linear Dose Responses Seen in Biomarker and Bone Mineral Density Data Pivotal Phase 3 registration study expected to...
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting
01 sept. 2021 08h30 HE
|
Entera Bio Ltd.
‒ Second of Two Presentations to be Delivered by Entera ‒ ‒ Final 6-Month Bone Mineral Density (BMD) Results Show Dose-Related Efficacy ‒ BOSTON and JERUSALEM, Sept. 01, 2021 (GLOBE...
Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021
23 août 2021 11h00 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its...
Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference
23 août 2021 08h30 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company’s CEO...
Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates
16 août 2021 06h30 HE
|
Entera Bio Ltd.
‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met ‒ ‒ Preparing for End of Phase 2 Meeting with FDA for...
Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021
13 août 2021 16h30 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business...
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting
02 août 2021 08h30 HE
|
Entera Bio Ltd.
‒ The Study’s Primary Endpoint was Met; P1NP, a Biochemical Marker of Bone Formation, was Significantly Increased at Month 3 in EB613 2.5 mg Treatment Group Versus Placebo ‒ ‒ Full 3-Month...